Updated:
NGM BIOPHARMACEUTICALS INC
NGM BIOPHARMACEUTICALS INC is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001426332, and its reported...
Overview
NGM BIOPHARMACEUTICALS INC is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001426332, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2024-03-11, it reported annual revenue of USD 4,417,000; net income of USD -142,375,000; total assets of USD 168,868,000 for the fiscal period ended 2023-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.
Company overview
- Legal name
- NGM BIOPHARMACEUTICALS INC
- Classification
- Company
- Industry (SIC)
- 2834 — Pharmaceutical Preparations
- Headquarters
- South San Francisco, CA, United States
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 0001426332
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|---|
| FY2023USD | $4.4M | -$142.4M | $168.9M | $55.8M | -$132.2M | |
| FY2022USD | $55.3M | -$162.7M | $307.4M | $73.5M | -$144.4M | |
| FY2021USD | $77.9M | -$120.3M | $402.4M | $151.8M | -$73.2M | |
| FY2020USD | $87.4M | -$102.5M | $329.0M | $147.0M | -$83.5M |
Recent SEC filings
| Form | Filed | Period | Filing |
|---|---|---|---|
| 8-K | 8-K | ||
| 10-K/A | 10-K/A | ||
| 10-K | 10-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research NGM BIOPHARMACEUTICALS INC in Altss
Track this company’s investors, transactions and relationships in Altss.